You'd best add the caveat of them being autlogous cells and not...

You'd best add the caveat of them being autlogous cells and not allogeneic, or you will get told off.

But indeed a significant milestone for the FDA as I posted in other threads, in that it is their first approval of genetically engineered CAR T-Cell therapy. - "TECELRA is a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T cell immunotherapy indicated for the treatment of adults with unresectable or metastatic synovial sarcoma...." (Adaptimmune)

I think the real relevancy for MSB is the nature of the approval:

"As part of the accelerated approval, a confirmatory trial will be required" (my embolden). It was granted on the back of a 44 patient trial. Another turning of the tide of the FDA approval regime that many have spoken about hopefully with regard to MSB on there threads.

https://www.fiercepharma.com/pharma/adaptimmune-scores-fda-nod-first-engineered-cell-therapy-solid-tumor

Another small positive development in the regulatory backdrop for MSB's FDA ambitions.